Research programme: oncolytic vaccinia virus therapy - SillaJen Biotherapeutics
Alternative Names: SJ-600 seriesLatest Information Update: 29 Aug 2023
At a glance
- Originator SillaJen Biotherapeutics
- Class Antineoplastics; Cancer vaccines; Oncolytic viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 24 Jul 2023 Preclinical trials in Solid tumours in USA (Parenteral) (SillaJen Biotherapeutics pipeline, July 2023)